BioCryst Pharmaceuticals News

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 0.2%. In

MT Newswires03:53

BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance

Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago.B

Benzinga02:59

BioCryst Pharmaceuticals, Freshpet Rise; Luminar, Integra Fall, Tuesday, 5/6/2024

Barchart00:35

Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session

Shares of Perficient, Inc (NASDAQ:PRFT) shares rose sharply during Monday's session after the company disclosed an acquisition deal and first-quarter FY24 results.The company stated that it has entere

Benzinga00:32

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 6 23:42

BioCryst Surges 18% on Quarterly Earnings, Adjusted Guidance Outlook

Seeking AlphaMay 6 22:36

BioCryst Pharma Shares Are Trading Higher Following Strong Q1 Results.

BioCryst Pharma Shares Are Trading Higher Following Strong Q1 Results.

BenzingaMay 6 19:13

Biocryst Pharmaceuticals Offers Insightful Corporate Update

TipRanksMay 6 19:12

BioCryst Pharma (BCRX.US): The 2024 Q1 financial report achieved revenue of US$92.761,000, previous value of US$687.78 million, expected value of US$85.6 million; earnings per share were -0.17 USD, previous value was -0.28 USD, and expected value was -0.2

BioCryst Pharma (BCRX.US): The 2024 Q1 financial report achieved revenue of US$92.761,000, previous value of US$687.78 million, expected value of US$85.6 million; earnings per share were -0.17 USD, previous value was -0.28 USD, and expected value was -0.21 USD.

Zhitong FinanceMay 6 19:11

Biocryst Forecasts 2024 Orladeyo Revenue Of $390M-$400M, The Top End Of Its Prior Guidance Range Of $380M-$400M

Biocryst Forecasts 2024 Orladeyo Revenue Of $390M-$400M, The Top End Of Its Prior Guidance Range Of $380M-$400M

BenzingaMay 6 19:05

BioCryst Pharmaceuticals Beats Top-line and Bottom-line Estimates; Updates FY24 Outlook

Seeking AlphaMay 6 19:04

BioCryst Pharma Q1 2024 Adj EPS $(0.17) Beats $(0.21) Estimate, Sales $92.761M Beat $85.605M Estimate

BioCryst Pharma Q1 2024 Adj EPS $(0.17) Beats $(0.21) Estimate, Sales $92.761M Beat $85.605M Estimate

BenzingaMay 6 19:03

BioCryst Pharmaceuticals Expects FY24 Global Net ORLADEYO Rev Between $390M and $400M >BCRX

BioCryst Pharmaceuticals Expects FY24 Global Net ORLADEYO Rev Between $390M and $400M >BCRX

Dow JonesMay 6 19:01

BioCryst Pharmaceuticals 1Q Loss/Shr 17c >BCRX

BioCryst Pharmaceuticals 1Q Loss/Shr 17c >BCRX

Dow JonesMay 6 19:00

Press Release: BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update --Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million-- --Full-year 2024 ORLADEYO revenue guidance

Dow JonesMay 6 19:00

Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More

Seeking AlphaMay 5 20:00

Press Release: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced th

Dow JonesMay 3 19:00

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing

Yahoo FinanceApr 22 20:04

BioCryst to Report First Quarter 2024 Financial Results on May 6

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,

GlobeNewswireApr 22 19:00